India Patent Office rejects Gilead’s Hep C drug patent application – Spicy IP

On Tuesday, 13th January 2015, the (Indian) Patent Office rejected Gilead’s attempt to patent Hepatitis C drug, sofosbuvir (brand name: Sovaldi). The application had earlier been opposed through 2 pre-grant oppositions – by generic pharmaceutical company Natco, and as well as by non-profit group I-MAK. While this is certainly good news for the 18 million Hepatitis C patients in India, it does throw up some very interesting questions vis-a-vis the Indian pharmaceutical landscape.

Read more – Spicy IP